Somryst® is the first and only prescription digital therapeutic indicated to treat chronic insomnia. Somryst is intended to improve insomnia symptoms by providing neurobehavioral intervention (cognitive behavioral therapy for insomnia – CBT-I) to adults 22 years of age and older with chronic insomnia.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solutions provide people everywhere with connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, life science companies and patients alike, Biofourmis’ connected platform improves patient outcomes, accelerates drug development, and closes critical gaps in care—ultimately making science smarter, healthcare simpler, and patients healthier.

Somryst provides a clinician facing dashboard that allows healthcare providers to track patient treatment and progress. The clinician dashboard displays information about patients’ use of Somryst, including the Insomnia Severity Index (ISI)1, the Patient Health Questionnaire 8 (PHQ-8)2 scores, and sleep metrics derived from nightly sleep diaries.